Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

Por Pepper, C, Buggins, A G S, Jones, C H, Walsby, E J, Forconi, F, Pratt, G, Devereux, S, Stevenson, F K, Fegan, C
Publicado no Leukemia (2015)

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

Por Carter, M J, Cox, K L, Blakemore, S J, Turaj, A H, Oldham, R J, Dahal, L N, Tannheimer, S, Forconi, F, Packham, G, Cragg, M S
Publicado no Leukemia (2017)

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

Por Parker, H, Rose-Zerilli, M J J, Larrayoz, M, Clifford, R, Edelmann, J, Blakemore, S, Gibson, J, Wang, J, Ljungström, V, Wojdacz, T K, Chaplin, T, Roghanian, A, Davis, Z, Parker, A, Tausch, E, Ntoufa, S, Ramos, S, Robbe, P, Alsolami, R, Steele, A J, Packham, G, Rodríguez-Vicente, A E, Brown, L, McNicholl, F, Forconi, F, Pettitt, A, Hillmen, P, Dyer, M, Cragg, M S, Chelala, C, Oakes, C C, Rosenquist, R, Stamatopoulos, K, Stilgenbauer, S, Knight, S, Schuh, A, Oscier, D G, Strefford, J C
Publicado no Leukemia (2016)